https://www.selleckchem.com/pr....oducts/fatostatin.ht
In the overall population, adalimumab significantly lowered absenteeism [mean (95% confidence interval) reduction, 18.9% (13.3-24.5%); = 100]; presenteeism [40.0% (33.8-46.3%); = 98], overall work productivity impairment [46.8% (40.4-53.2%); = 94], activity impairment [47.0% (44.3-49.6); = 421], and the MOS-SS sleep problems index [31.6 (29.5-34.1); = 421] after 24-month treatment ( 0.001). Significant improvements were also noted across the RA, PsA, and AS subpopulations ( 0.05). Improvements in overall work impairm
Like
Comment
Share
